Cantor Fitzgerald Predicts ALX Oncology FY2026 Earnings

ALX Oncology Holdings Inc. (NASDAQ:ALXO) – Investment analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for shares of ALX Oncology in a report issued on Monday, June 9th. Cantor Fitzgerald analyst L. Watsek anticipates that the company will post earnings of ($1.52) per share for the year. The consensus estimate for ALX Oncology’s current full-year earnings is ($2.76) per share.

ALX Oncology (NASDAQ:ALXO) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.11).

Several other research firms also recently issued reports on ALXO. Stifel Nicolaus reduced their price target on ALX Oncology from $3.00 to $1.50 and set a “hold” rating for the company in a research note on Friday, March 7th. Wall Street Zen cut shares of ALX Oncology from a “hold” rating to a “sell” rating in a research report on Friday. Jefferies Financial Group upgraded shares of ALX Oncology from a “hold” rating to a “buy” rating and increased their price target for the stock from $2.00 to $3.00 in a research report on Thursday, March 6th. HC Wainwright lowered their price objective on shares of ALX Oncology from $5.00 to $2.00 and set a “buy” rating for the company in a research report on Friday, May 9th. Finally, UBS Group decreased their price target on ALX Oncology from $1.20 to $1.00 and set a “buy” rating on the stock in a research note on Wednesday, May 21st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $3.30.

ALX Oncology Trading Down 4.1%

Shares of ALX Oncology stock opened at $0.56 on Tuesday. The stock has a market cap of $29.63 million, a P/E ratio of -0.19 and a beta of 1.16. ALX Oncology has a 12-month low of $0.41 and a 12-month high of $9.04. The business’s 50 day moving average is $0.51 and its 200-day moving average is $1.04. The company has a quick ratio of 4.82, a current ratio of 4.82 and a debt-to-equity ratio of 0.07.

Hedge Funds Weigh In On ALX Oncology

Several hedge funds and other institutional investors have recently bought and sold shares of ALXO. Almitas Capital LLC bought a new position in shares of ALX Oncology in the 4th quarter worth about $2,042,000. Bank of America Corp DE increased its holdings in ALX Oncology by 492.9% in the fourth quarter. Bank of America Corp DE now owns 1,035,326 shares of the company’s stock worth $1,729,000 after purchasing an additional 860,703 shares in the last quarter. Bank of Montreal Can acquired a new position in ALX Oncology in the fourth quarter valued at approximately $1,380,000. Two Sigma Advisers LP boosted its holdings in shares of ALX Oncology by 64.6% during the 4th quarter. Two Sigma Advisers LP now owns 823,900 shares of the company’s stock worth $1,376,000 after buying an additional 323,400 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its stake in shares of ALX Oncology by 476.7% in the 4th quarter. JPMorgan Chase & Co. now owns 236,046 shares of the company’s stock valued at $394,000 after acquiring an additional 195,112 shares in the last quarter. Institutional investors and hedge funds own 97.97% of the company’s stock.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.